Key Points:
– A growing backlog of overseas FDA inspections may delay new drug approvals.
– Over 2,000 drug manufacturers haven’t been inspected since before the pandemic.
– Quality issues with manufacturing have already affected new drug launches.
The Impact of the Pandemic on FDA Inspections
The COVID-19 pandemic halted inspections of overseas drug manufacturers, leading to a backlog that is still causing ripple effects in the pharmaceutical industry. As of now, over 2,000 pharmaceutical manufacturers have gone without inspection by the FDA since before the pandemic. This delay could result in slowed approval for new drugs.
A recent analysis from the Associated Press sheds light on the risks posed by this inspection gap, a concern echoed by the Government Accountability Office and lawmakers. In some cases, unresolved quality issues have even impacted drug approvals.
Why the Delays Matter
David Ridley, an economics professor at Duke University, pointed out that delays in overseas inspections can affect U.S. pharmaceutical companies that rely on third-party manufacturers. For instance, AbbVie’s potential Parkinson’s disease drug faced its second rejection due to concerns at a third-party manufacturing facility. Rocket Pharmaceuticals and Merck & Co. have also faced similar FDA rejections, all related to manufacturing issues.
Ridley emphasizes that these delays have a significant impact on patient care. “Some good medicines are getting to patients later,” he explained.
Concerns Over Inspection Standards
Beyond the backlog, concerns have been raised about the FDA’s inspection process itself. A congressional report from June highlighted inconsistencies in inspection outcomes in countries like India and China. While some inspectors found compliance issues in nearly all inspections, others reported none at all. This discrepancy has raised questions about the consistency and quality of FDA inspections.
The Risk to Generic Drugs
Generic drugs, which are often manufactured overseas, could be especially vulnerable to quality concerns. According to Ridley, the cost-cutting pressure on generic drug manufacturers could lead some to “skimp on quality,” particularly if they believe inspections are unlikely. This poses a risk to the safety and efficacy of generic medications that many patients rely on.
FDA’s Response
The FDA has acknowledged the backlog and is working to resolve the issue. However, staffing shortages remain a significant hurdle. Recruiting inspectors willing to travel has proven difficult, especially with the constraints of government pay.
If the FDA is unable to address the backlog soon, Ridley suggests that drug retailers or wholesalers may need to take on more responsibility for ensuring pharmaceutical quality.
Looking Ahead
The backlog in FDA inspections is a complex issue that could affect both new and generic drug approvals. “We should be concerned about the quality and efficacy of our generic drugs,” Ridley warns, urging more attention to the sector to prevent future problems.